The pharmaceutical industry comes under Healthcare group. It’s a Non-commodity type industry.

Industry Strengths

Growing demand as lifestyles continue to become sedentary leading to particular disorders.
Inelastic demand for basic medicines for chronic illnesses.
Low R&D, trial and production costs especially for generics.
Access to foreign markets due to mergers and acquisitions and strategic tie-ups.

Industry Weakness

Uncertain government regulations on pricing
High competition from foreign companies
Dependence of regulators in developed markets
High risk of litigations and patents disputes especially in developed markets

Growth Drivers

Growing population with higher life expectancy and greater number of old people
Awareness of latest medicine technologies
Increasing lifestyle disorders such as diabetes, cardiac and obesity
Very strong demand for generics in developed and domestic markets due to its cheap pricing.
Growth in hospital and healthcare sector

Lupin is a pharmaceutical company and a leading generic player from India. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

US and India are its largest markets and contribute almost 60% of its revenues and boasts of significant presence in Japan (unlike most other generic players). While in India it is among the top-10 companies and among the fastest growing, it is among top-5 companies in terms of prescriptions in the US. To top that, it entered the Japan market well before other generic players and is now among the top-10 generic companies in Japan.

The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil.

Segments and Products

The Company offers products in the

1.cardiovascular,
2.diabetology,
3.asthma,
4.pediatrics,
5.central nervous system,
6.gastro-intestinal,
7.anti-infectives and
8.non-steroidal anti-inflammatory drug therapy areas.

The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas.

It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health.
The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.